NASDAQ:CYTK
Cytokinetics Stock News
$71.41
+0.260 (+0.365%)
At Close: Mar 27, 2024
Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells $675,000.00 in Stock
01:08am, Friday, 24'th Dec 2021 Dakota Financial News
Cytokinetics, Incorporated (NASDAQ:CYTK) Director Edward M. Md Kaye sold 15,000 shares of the stock in a transaction on Thursday, December 23rd. The stock was sold at an average price of $45.00, for a total value of $675,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. []
Oppenheimer Initiates Coverage on Cytokinetics (NASDAQ:CYTK)
07:56am, Thursday, 23'rd Dec 2021 ETF Daily News
Equities researchers at Oppenheimer started coverage on shares of Cytokinetics (NASDAQ:CYTK) in a report released on Tuesday, The Fly reports. The brokerage set an outperform rating and a $55.00 price target on the biopharmaceutical companys stock. Oppenheimers price target indicates a potential upside of 24.94% from the companys current price. CYTK has been the subject [] The post Oppenheimer Initiates Coverage on Cytokinetics (NASDAQ:CYTK) appeared first on ETF Daily News .
Cytokinetics (NASDAQ:CYTK) Hits New 1-Year High on Analyst Upgrade
06:10pm, Wednesday, 22'nd Dec 2021 Transcript Daily
Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) reached a new 52-week high on Wednesday after HC Wainwright raised their price target on the stock from $62.00 to $69.00. HC Wainwright currently has a buy rating on the stock. Cytokinetics traded as high as $43.70 and last traded at $43.70, with a volume of 10808 shares traded. The []
Cytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokinetics
12:30pm, Monday, 20'th Dec 2021 GlobeNewswire Inc.
JI XING to Develop and CommercializeNovel Cardiac Myosin Activator in Patients with Heart Failure
Cytokinetics (NASDAQ:CYTK) Receives New Coverage from Analysts at JPMorgan Chase & Co.
07:56am, Monday, 13'th Dec 2021 Transcript Daily
JPMorgan Chase & Co. started coverage on shares of Cytokinetics (NASDAQ:CYTK) in a research note issued to investors on Friday morning, Analyst Price Targets reports. The brokerage issued an overweight rating and a $58.00 target price on the biopharmaceutical companys stock. Several other equities research analysts have also recently commented on CYTK. Mizuho boosted their []
Is Cytokinetics, Inc. (CYTK) Going to Burn These Hedge Funds?
08:51pm, Sunday, 12'th Dec 2021 Insider MonkeyCytokinetics' (CYTK) Aficamten Gets Breakthrough Therapy Tag
03:21pm, Friday, 10'th Dec 2021 Zacks Investment Research
The FDA bestows a Breakthrough Therapy status on Cytokinetics' (CYTK) aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Global Spinal Muscular Atrophy Treatment Market (2021 to 2026) - Featuring Astellas Pharma, Biogen and Cytokinetics Among Others - ResearchAndMarkets.com
02:43pm, Friday, 10'th Dec 2021 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Global Spinal Muscular Atrophy Treatment Market (2021-2026) by Disease Type, Treatment, Route of Administration and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com''s offering. The Global Spinal Muscular Atrophy Treatment Market is estimated to be USD 1.1 Bn in 2021 and is expected to reach USD 1.98 Bn by 2026, growing at a CAGR of 12.5%. The SMA treatment market is growing at a signifi
Cytokinetics Announces Data From Its ALS Program Presented at the 32nd International Symposium on ALS/MND
12:30pm, Friday, 10'th Dec 2021 GlobeNewswire Inc.
Majority of Initial Patients Enrolled in COURAGE-ALS Show Intended Middle to Fast Disease Progression Phenotype at Baseline Majority of Initial Patients Enrolled in COURAGE-ALS Show Intended Middle to
Cytokinetics' (CYTK) Aficamten Gets Breakthrough Therapy Tag
11:30am, Friday, 10'th Dec 2021
The FDA bestows a Breakthrough Therapy status on Cytokinetics' (CYTK) aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells $1,064,267.34 in Stock
01:12am, Friday, 10'th Dec 2021 Transcript Daily
Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 29,166 shares of the businesss stock in a transaction dated Thursday, December 9th. The stock was sold at an average price of $36.49, for a total value of $1,064,267.34. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Fady []
Cytokinetics Announces Receipt of Breakthrough Therapy Designation from FDA for Aficamten
12:30pm, Thursday, 09'th Dec 2021 GlobeNewswire Inc.
FDA Granted Designation for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy Based on Results of REDWOOD-HCM FDA Granted Designation for the Treatment of Symptomatic Obstructive Hy
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
01:17pm, Tuesday, 07'th Dec 2021 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome
Acadia Pharmaceuticals Inc. (N
Cytokinetics (NASDAQ:CYTK) Downgraded to Sell at Zacks Investment Research
06:14am, Tuesday, 07'th Dec 2021 Transcript Daily
Zacks Investment Research lowered shares of Cytokinetics (NASDAQ:CYTK) from a hold rating to a sell rating in a report released on Friday, Zacks.com reports. According to Zacks, Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or []
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
11:07am, Monday, 06'th Dec 2021 Benzinga
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r